In 1988, he joined the DuPont Pharmaceutical Company, where he worked both as a bench scientist on HIV drug resistance then later designed the clinical trials eventually leading to the FDA approval of Sustiva (efavirenz).
He joined the DuPont Pharmaceutical Company. This was in 1988. He worked both as a bench scientist on HIV drug resistance (efavirenz). This HIV drug resistance was then later designed the clinical trials eventually leading to the FDA approval of Sustiva.